Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin

M. E. Potter, Kenneth D Hatch, M. Y. Potter, H. M. Shingleton, V. V. Baker

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

From June 1977 to June 1987 74 patients were treated with cisplatin for recurrent squamous cell carcinoma of the cervix as the primary chemotherapeutic agent. Sixty-eight patients were evaluable for response or survival. Patients with disease confined to the chest had a 53% complete response rate with an overall response rate of 73%. Patients with localized pelvic recurrences or persistence demonstrated no complete responses and a 21% overall response rate. Isolated chest metastases are more likely to respond to cisplatin than pelvic recurrences (P = 0.0007); however, location of recurrence did not significantly alter survival (mean 22.7 months versus 14.1 months; P = 0.24). Concomitant disease in other locations reduced the likelihood of response in the chest (P < 0.05) by virtue of lack of response in those other sites. Lesion size, clinical stage, patient age, and duration from primary treatment to recurrence were not of significance with regard to response or survival. When evaluating response to chemotherapy in recurrent cervical cancer, location of metastasis and effect on survival must be considered.

Original languageEnglish (US)
Pages (from-to)1283-1286
Number of pages4
JournalCancer
Volume63
Issue number7
StatePublished - 1989
Externally publishedYes

Fingerprint

Cervix Uteri
Cisplatin
Squamous Cell Carcinoma
Recurrence
Thorax
Survival
Neoplasm Metastasis
Uterine Cervical Neoplasms
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Potter, M. E., Hatch, K. D., Potter, M. Y., Shingleton, H. M., & Baker, V. V. (1989). Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer, 63(7), 1283-1286.

Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. / Potter, M. E.; Hatch, Kenneth D; Potter, M. Y.; Shingleton, H. M.; Baker, V. V.

In: Cancer, Vol. 63, No. 7, 1989, p. 1283-1286.

Research output: Contribution to journalArticle

Potter, ME, Hatch, KD, Potter, MY, Shingleton, HM & Baker, VV 1989, 'Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin', Cancer, vol. 63, no. 7, pp. 1283-1286.
Potter, M. E. ; Hatch, Kenneth D ; Potter, M. Y. ; Shingleton, H. M. ; Baker, V. V. / Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. In: Cancer. 1989 ; Vol. 63, No. 7. pp. 1283-1286.
@article{7dd5be1be2764d4a8ebd3ecb7a0d1f3c,
title = "Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin",
abstract = "From June 1977 to June 1987 74 patients were treated with cisplatin for recurrent squamous cell carcinoma of the cervix as the primary chemotherapeutic agent. Sixty-eight patients were evaluable for response or survival. Patients with disease confined to the chest had a 53{\%} complete response rate with an overall response rate of 73{\%}. Patients with localized pelvic recurrences or persistence demonstrated no complete responses and a 21{\%} overall response rate. Isolated chest metastases are more likely to respond to cisplatin than pelvic recurrences (P = 0.0007); however, location of recurrence did not significantly alter survival (mean 22.7 months versus 14.1 months; P = 0.24). Concomitant disease in other locations reduced the likelihood of response in the chest (P < 0.05) by virtue of lack of response in those other sites. Lesion size, clinical stage, patient age, and duration from primary treatment to recurrence were not of significance with regard to response or survival. When evaluating response to chemotherapy in recurrent cervical cancer, location of metastasis and effect on survival must be considered.",
author = "Potter, {M. E.} and Hatch, {Kenneth D} and Potter, {M. Y.} and Shingleton, {H. M.} and Baker, {V. V.}",
year = "1989",
language = "English (US)",
volume = "63",
pages = "1283--1286",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin

AU - Potter, M. E.

AU - Hatch, Kenneth D

AU - Potter, M. Y.

AU - Shingleton, H. M.

AU - Baker, V. V.

PY - 1989

Y1 - 1989

N2 - From June 1977 to June 1987 74 patients were treated with cisplatin for recurrent squamous cell carcinoma of the cervix as the primary chemotherapeutic agent. Sixty-eight patients were evaluable for response or survival. Patients with disease confined to the chest had a 53% complete response rate with an overall response rate of 73%. Patients with localized pelvic recurrences or persistence demonstrated no complete responses and a 21% overall response rate. Isolated chest metastases are more likely to respond to cisplatin than pelvic recurrences (P = 0.0007); however, location of recurrence did not significantly alter survival (mean 22.7 months versus 14.1 months; P = 0.24). Concomitant disease in other locations reduced the likelihood of response in the chest (P < 0.05) by virtue of lack of response in those other sites. Lesion size, clinical stage, patient age, and duration from primary treatment to recurrence were not of significance with regard to response or survival. When evaluating response to chemotherapy in recurrent cervical cancer, location of metastasis and effect on survival must be considered.

AB - From June 1977 to June 1987 74 patients were treated with cisplatin for recurrent squamous cell carcinoma of the cervix as the primary chemotherapeutic agent. Sixty-eight patients were evaluable for response or survival. Patients with disease confined to the chest had a 53% complete response rate with an overall response rate of 73%. Patients with localized pelvic recurrences or persistence demonstrated no complete responses and a 21% overall response rate. Isolated chest metastases are more likely to respond to cisplatin than pelvic recurrences (P = 0.0007); however, location of recurrence did not significantly alter survival (mean 22.7 months versus 14.1 months; P = 0.24). Concomitant disease in other locations reduced the likelihood of response in the chest (P < 0.05) by virtue of lack of response in those other sites. Lesion size, clinical stage, patient age, and duration from primary treatment to recurrence were not of significance with regard to response or survival. When evaluating response to chemotherapy in recurrent cervical cancer, location of metastasis and effect on survival must be considered.

UR - http://www.scopus.com/inward/record.url?scp=0024555993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024555993&partnerID=8YFLogxK

M3 - Article

C2 - 2920357

AN - SCOPUS:0024555993

VL - 63

SP - 1283

EP - 1286

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -